Avalo Therapeutics, Inc. Q3 FY2022 Earnings Call

Avalo Therapeutics, Inc. (AVTX)

Earnings Call FY2022 Q3 Call date: 2022-11-07 Concluded

Quarter scorecard

Revenue

$14.95M

+1007.3% YoY

Diluted EPS

$81.60

Net income

$3.19M

License $14.52M

Product $432,000

-68%